Literature DB >> 1560382

An investigation of the acute effect of gentamicin on the renal handling of electrolytes in the rat.

J E Foster1, E S Harpur, H O Garland.   

Abstract

Standard renal clearance techniques were used to investigate the acute effects of gentamicin on renal electrolyte handling in anesthetized rats. Data were obtained before substantial changes in tubular integrity would be expected to occur, thus permitting a distinction between the actions of the drug per se and renal changes resulting from underlying tubular damage. Infusion of gentamicin over a 3-hr period resulted in an immediate and sustained calciuresis and magnesiuresis, with no significant change in the renal clearance of sodium or potassium. Within 60 min of the onset of drug infusion at 0.28 mg/kg/min, renal calcium clearance (ml/min) increased from 0.095 +/- 0.013 to 0.210 +/- 0.016 (P less than .001) and renal magnesium clearance (ml/min) increased from 0.538 +/- 0.059 to 0.662 +/- 0.053 (P less than .01). Because it was subsequently shown that infusion of gentamicin did not alter glomerular filtration rate, it is clear that both responses resulted from a reduced tubular reabsorption of the respective ions; they were rapidly reversible when gentamicin infusion ceased. A higher dose of gentamicin (0.56 mg/kg/min for 3 hr) also significantly decreased plasma magnesium concentrations (0.40 +/- 0.01 vs. 0.49 +/- 0.02 mmol/l, treated vs. control; P less than .01). Gentamicin-induced changes in the renal handling of calcium and magnesium, therefore, occur independently of and before the development of nephrotoxicity. They may be at least partially responsible for the alteration in electrolyte homeostasis seen in humans during aminoglycoside treatment (e.g., hypomagnesemia). It is interesting to speculate on the possibility that they may also in some way contribute to the subsequent cellular injury that is known to occur with prolonged use of gentamicin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560382

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Association of hypocalcemia with a change in gentamicin administration in neonates.

Authors:  Gregory L Jackson; Dorothy M Sendelbach; Elizabeth K Stehel; Michel Baum; M Denise Manning; William D Engle
Journal:  Pediatr Nephrol       Date:  2003-05-15       Impact factor: 3.714

2.  Clinical significance of fractional magnesium excretion (FEMg) as a predictor of interstitial nephropathy and its correlation with conventional parameters.

Authors:  Chie Noiri; Taisuke Shimizu; Kaori Takayanagi; Yosuke Tayama; Takatsugu Iwashita; Shimpei Okazaki; Minoru Hatano; Osamu Matsumura; Hitoshi Kato; Akihiko Matsuda; Tetsuya Mitarai; Hajime Hasegawa
Journal:  Clin Exp Nephrol       Date:  2015-02-28       Impact factor: 2.801

Review 3.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Localization of the nephron site of gentamicin-induced hypercalciuria in the rat: a micropuncture study.

Authors:  P P Parsons; H O Garland; E S Harpur
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

5.  Gentamicin Inhibits Ca2+ Channel TRPV5 and Induces Calciuresis Independent of the Calcium-Sensing Receptor-Claudin-14 Pathway.

Authors:  Wouter H van Megen; Megan R Beggs; Sung-Wan An; Patrícia G Ferreira; Justin J Lee; Matthias T Wolf; R Todd Alexander; Henrik Dimke
Journal:  J Am Soc Nephrol       Date:  2022-01-12       Impact factor: 10.121

6.  Acute effects of gentamicin on urinary electrolyte excretion in neonates.

Authors:  Vasilios I Giapros; Vasilios I Cholevas; Styliani K Andronikou
Journal:  Pediatr Nephrol       Date:  2003-12-20       Impact factor: 3.714

7.  Hyperbaric oxygen treatment and nephrotoxicity induced by gentamicin in rats.

Authors:  Matitiahu Berkovitch; Yossi Shain; Eran Kozer; Michael Goldman; Ibrahim Abu-Kishk
Journal:  BMC Nephrol       Date:  2017-12-02       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.